



Tandem Diabetes Care  
Investor Relations Department  
11025 Roselle Street  
San Diego, CA 92121  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**NASDAQ: TNDM** <sup>1</sup>

|                   |  |
|-------------------|--|
| Last Trade:       | 2.91   |
| Trade Time:       | 4:00 PM ET<br>Jan 19, 2018                         |
| Change:           | 0.03 <span style="color: green;">↑</span> (1.042%) |
| Day Range         | 2.83 - 3.02  |
| 52-Week Range     | 2.15 - 30.00                                       |
| Volume            | 826,706  |
| Market Cap. (\$M) | 29.449   |
| Shares Out (M)    | 10.120   |

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

### Our Company

Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2™ Insulin Pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Tandem Diabetes Care's financial performance into perspective.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

*Jan 9, 2018*  
[Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance](#)

*Jan 8, 2018*  
[Tandem Diabetes Care Reports Successful Completion of First Pilot Study Using t:slim X2 Insulin Pump with TypeZero Hybrid Closed Loop Technology and Dexcom G6 Integration: Confirms IDCL Multi-site Study Timeline](#)

*Jan 3, 2018*  
[Tandem Diabetes Care Commences Full Manufacturing Operations at New San Diego Facility](#)

*Dec 14, 2017*  
[Tandem Diabetes Care Announces Issuance of Patent Related to Automated Insulin Delivery Technology](#)

*Dec 7, 2017*  
[Tandem Diabetes Care Announces Retirement of CFO and Successor Appointment](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 8, 2017*  
[Annual Report \(10-K\)](#)

*Jul 27, 2017*  
[Definitive Proxy Statement](#)

*Oct 26, 2017*  
[Quarterly Report \(10-Q\)](#)

*Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)

*Apr 27, 2017*  
[Quarterly Report \(10-Q\)](#)